# Use of Sitagliptin to Decrease Microalbuminuria

> **NCT02048904** · PHASE4 · TERMINATED · sponsor: **University of Missouri-Columbia** · enrollment: 142 (actual)

## Conditions studied

- Type 2 Diabetes
- Microalbuminuria

## Interventions

- **DRUG:** Sitagliptin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02048904
- **Lead sponsor:** University of Missouri-Columbia
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-01
- **Primary completion:** 2016-01
- **Final completion:** 2016-06
- **Target enrollment:** 142 (ACTUAL)
- **Why stopped:** Original Principal Investigator left institution. No data analyzed.
- **Last updated:** 2017-08-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02048904

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02048904, "Use of Sitagliptin to Decrease Microalbuminuria". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02048904. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*